Literature DB >> 19548121

Antifibrosis: to reverse the irreversible.

Ziv Paz1, Yehuda Shoenfeld.   

Abstract

Fibrosis is a pathological process that includes scar formation and overproduction of extracellular matrix by the connective tissue as a response to tissue damage. The fibrotic process involves multiple organs and results in progressive life-threatening diseases. Today, we know more about the molecular mechanism that leads to fibrosis involving different type of cells, cytokines, chemokines, and tissue enzymes. Fibrosis was considered an irreversible process, at least clinically, and is still usually treated by anti-inflammatory and immunosuppressive agents. No proven antifibrotic therapy has shown efficacy in ameliorating the clinical course of fibrotic diseases, but our current understanding led to the development of different drugs with promising results, like: mycophenolate mofetil, interferon, relaxin, and intravenous immunoglobulin. This review will provide a glance to this heavily investigated subject.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19548121     DOI: 10.1007/s12016-009-8157-7

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  133 in total

1.  Relaxins: lessons and limitations.

Authors:  James R Seibold
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

2.  Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.

Authors:  Ganesh Raghu; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Roland M du Bois; Joseph A Lasky; Michiel Thomeer; James P Utz; Rezaul K Khandker; Lawrence McDermott; Saeed Fatenejad
Journal:  Am J Respir Crit Care Med       Date:  2008-07-31       Impact factor: 21.405

3.  A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation.

Authors:  Hans-Joachim Anders; Volker Vielhauer; Michael Frink; Yvonne Linde; Clemens D Cohen; Simone M Blattner; Matthias Kretzler; Frank Strutz; Matthias Mack; Hermann-Josef Gröne; James Onuffer; Richard Horuk; Peter J Nelson; Detlef Schlöndorff
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

4.  Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin--a preliminary report.

Authors:  Y Levy; Y Sherer; P Langevitz; M Lorber; P Rotman; F Fabrizzi; Y Shoenfeld
Journal:  Clin Rheumatol       Date:  2000       Impact factor: 2.980

5.  Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine.

Authors:  J Behr; B Degenkolb; F Krombach; C Vogelmeier
Journal:  Eur Respir J       Date:  2002-05       Impact factor: 16.671

Review 6.  D-penicillamine is not an effective treatment in systemic sclerosis.

Authors:  D E Furst; P J Clements
Journal:  Scand J Rheumatol       Date:  2001       Impact factor: 3.641

7.  Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone.

Authors:  W C Cain; R W Stuart; D L Lefkowitz; J D Starnes; S Margolin; S S Lefkowitz
Journal:  Int J Immunopharmacol       Date:  1998-12

8.  Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis.

Authors:  A W Cheever; M E Williams; T A Wynn; F D Finkelman; R A Seder; T M Cox; S Hieny; P Caspar; A Sher
Journal:  J Immunol       Date:  1994-07-15       Impact factor: 5.422

9.  Retroperitoneal fibrosis treated with methylprednisolon pulse and disease-modifying antirheumatic drugs.

Authors:  M Harreby; T Bilde; P Helin; H H Meyhoff; H Vinterberg; V A Nielsen
Journal:  Scand J Urol Nephrol       Date:  1994-09

Review 10.  Smad3: a key player in pathogenetic mechanisms dependent on TGF-beta.

Authors:  Anita B Roberts; Angelo Russo; Angelina Felici; Kathleen C Flanders
Journal:  Ann N Y Acad Sci       Date:  2003-05       Impact factor: 5.691

View more
  12 in total

1.  Microtopographical cues in 3D attenuate fibrotic phenotype and extracellular matrix deposition: implications for tissue regeneration.

Authors:  Perla Ayala; Jose I Lopez; Tejal A Desai
Journal:  Tissue Eng Part A       Date:  2010-08       Impact factor: 3.845

2.  Sequential Release of Multiple Drugs from Flexible Drug Delivery Films.

Authors:  Cheryl L Jennings; Ellis K Perry; Thomas D Dziubla; David A Puleo
Journal:  Int J Polym Mater       Date:  2017-01-04       Impact factor: 2.604

Review 3.  Scarless wound healing.

Authors:  Ian H Bellayr; Thomas J Walters; Yong Li
Journal:  J Am Col Certif Wound Spec       Date:  2010-01-11

4.  The future of autoimmunity.

Authors:  Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2012-04       Impact factor: 8.667

5.  Themes in fibrosis and gastrointestinal inflammation.

Authors:  Claudio Fiocchi; P Kay Lund
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-03-17       Impact factor: 4.052

Review 6.  Green tea polyphenols and their potential role in health and disease.

Authors:  M Afzal; A M Safer; M Menon
Journal:  Inflammopharmacology       Date:  2015-07-12       Impact factor: 4.473

7.  Curative propensity of green tea extract towards hepatic fibrosis induced by CCl(4): A histopathological study.

Authors:  A M Safer; M Afzal; A Nomani; O Sosamma; S A Mousa
Journal:  Exp Ther Med       Date:  2012-03-02       Impact factor: 2.447

8.  Differentiating Glomerular Inflammation from Fibrosis in a Bone Marrow Chimera for Rat Anti-Glomerular Basement Membrane Glomerulonephritis.

Authors:  Cindy Zhou; Kristie Lou; Kiana Tatum; Jeremiah Funk; Jean Wu; Todd Bartkowiak; David Kagan; Yahuan Lou
Journal:  Am J Nephrol       Date:  2015       Impact factor: 3.754

9.  Green tea extract therapy diminishes hepatic fibrosis mediated by dual exposure to carbon tetrachloride and ethanol: A histopathological study.

Authors:  Abdel-Majeed Safer; Mohamad Afzal; Nomny Hanafy; Shaker Mousa
Journal:  Exp Ther Med       Date:  2014-12-24       Impact factor: 2.447

Review 10.  Role and New Insights of Pirfenidone in Fibrotic Diseases.

Authors:  David Alejandro Lopez-de la Mora; Cibeles Sanchez-Roque; Margarita Montoya-Buelna; Sergio Sanchez-Enriquez; Silvia Lucano-Landeros; Jose Macias-Barragan; Juan Armendariz-Borunda
Journal:  Int J Med Sci       Date:  2015-10-14       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.